Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to 47.58%.

  • Ligand Pharmaceuticals' EBIT Margin rose 415100.0% to 47.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.97%, marking a year-over-year increase of 176900.0%. This contributed to the annual value of 13.53% for FY2024, which is 226200.0% down from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' EBIT Margin is 47.58%, which was up 415100.0% from 17.73% recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' EBIT Margin registered a high of 66.82% during Q4 2021, and its lowest value of 79.89% during Q1 2025.
  • For the 5-year period, Ligand Pharmaceuticals' EBIT Margin averaged around 6.32%, with its median value being 9.65% (2024).
  • Per our database at Business Quant, Ligand Pharmaceuticals' EBIT Margin plummeted by -1067100bps in 2022 and then skyrocketed by 637200bps in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' EBIT Margin (Quarter) stood at 66.82% in 2021, then tumbled by -160bps to 39.89% in 2022, then soared by 70bps to 11.95% in 2023, then crashed by -88bps to 22.51% in 2024, then soared by 311bps to 47.58% in 2025.
  • Its EBIT Margin stands at 47.58% for Q3 2025, versus 17.73% for Q2 2025 and 79.89% for Q1 2025.